
    
      -  Participants will receive one of two treatment possibilities. Since no one knows which
           of the study options is best, participants will be "randomized" to one fo the three
           treatment groups.

        -  Group 1 will stop their current treatment with sunitinib and receive a dose of
           bevacizumab once every 2 weeks. Group 2 will receive the standard treatment of sunitinib
           with the addition of bevacizumab.

        -  All study participants will undergo the same study procedures. These study procedures
           will include the following at intervals specified in the protocol: medical history
           review; vital signs; physical exam; urine analysis; EKG and CT scan.
    
  